Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.65 CAD | -.--% | -2.11% | +17.72% |
04-08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
03-14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.72% | 108M | |
+14.71% | 70.59B | |
+1.36% | 25.06B | |
+7.11% | 8.2B | |
-20.55% | 7.96B | |
-5.13% | 7.92B | |
+3.91% | 4.71B | |
+17.12% | 4.32B | |
-1.24% | 4.01B | |
-3.44% | 3.82B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics : Q2 Net Loss Narrows YoY to US$0.07 Per Share; Revenue Up to Nearly US$15 Million